To ensure the use of pre-exposure prophylaxis (PrEP) for HIV infection and thereby decrease the incidence of HIV, continued use of an effective dosage of preventive therapy is essential. However, research...
In a recent study, researchers examined how HIV pre-exposure prophylaxis training varied during residency training across areas of various population sizes within the United States.
To determine the number and characteristics of PrEP providers in the United States, researchers analyzed data from a national pharmacy database, which included more than 90% of all prescriptions dispensed...
New findings presented at AIDS 2020: Virtual indicate that a PrEP regimen containing this long-acting injectable drug demonstrated superiority to daily oral tenofovir/emtricitabine in preventing HIV among...
The Centers for Disease Control and Prevention has released guidance on what to consider when evaluating adolescents for pre-exposure prophylaxis for the prevention of HIV.
The FDA has approved a new option for HIV-1 pre-exposure prophylaxis to reduce HIV-1 infection risk from sex, excluding in those who have receptive vaginal sex.
In his session as IAS 2019, Myron Cohen, MD, discussed new long-acting injectables for HIV prevention and the ongoing trials that will determine the efficacy of each.
The impact of tenofovir-containing pre-exposure prophylaxis on bone mineral density may vary depending on an individual’s adherence. Authors of a new study assessed the effect of the only FDA-approved PrEP...
